Neuros Medical, the maker of the FDA-approved Altius Direct Electrical Nerve Stimulation System for chronic post-amputation pain, announced an oversubscribed $56 million Series D financing round. The funding, led by EQT Life Sciences with participation from existing investors, will support the U.S. commercialization and further development of its breakthrough non-opioid treatment.
KEY QUOTES:
“I would like to thank our new and existing investors for their support in our mission to relieve pain and restore life for the millions of people suffering from chronic post-amputation pain. This funding round is a strong validation of the unmet medical need in the amputee community and allows us to scale our commercial operations to expand access to this breakthrough technology, while equipping healthcare professionals with a non-opioid solution and support they need to deliver the highest standard of care.”
David Veino, President & CEO, Neuros Medical
“Neuros Medical is addressing one of the most urgent and overlooked challenges in chronic pain management. EQT believes Altius has the potential to significantly improve the quality of life for amputees, and we are proud to partner with this team to bring the therapy to market.”
Fouad Azzam, Ph.D., Partner in the EQT Life Sciences advisory team
